Coenzyme Q10: A therapy for hypertension and statin-induced myalgia?

Cleveland Clinic Journal of Medicine

Volumn 77, Issue 7, 2010, Pages 435-442

  Wyman, Marcia ^a   Leonard, Mandy ^a   Morledge, Thomas ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UBIDECARENONE; UBIQUINONE; VITAMIN;

CHEMICALLY INDUCED DISORDER; DIET SUPPLEMENTATION; HUMAN; HYPERTENSION; MUSCLE DISEASE; REVIEW; RISK ASSESSMENT;

ANTIHYPERTENSIVE AGENTS; DIETARY SUPPLEMENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MUSCULAR DISEASES; RISK ASSESSMENT; UBIQUINONE; VITAMINS;

EID: 77954685883     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77a.09078     Document Type: Review

References (48)

1. Jelin JM, Gregory PJ, et al. Natural medicines comprehensive database/compiled by the editors of Pharmacist's Letter, Prescriber's Letter. 11th ed. Stockton, CA: Therapeutic Research Faculty; 2009:452-457.
2. Fetrow CW, Avila JR. Professional's Handbook of Complementary & Alternative Medicines. 2nd ed. Springhouse, PA: Springhouse; 2001:211-215.
3. Yamagami T, Takagi M, Akagami H, et al. Effect of coenzyme Q10 on essential hypertension, a double-blind controlled study. In: Folkers K, Yamamura Y, editors. Biomedical and Clinical Aspects of Coenzyme Q10: Proceedings of the Fifth International Symposium on the Biomedical and Clinical Aspects of Coenzyme Q10, vol 5. Amsterdam: Elsevier Science Publishers; 1986:337-343.
4. Digiesi V, Cantini F, Oradei A, et al. Coenzyme Q10 in essential hypertension. Mol Aspects Med 1994; 15(suppl):S257-S263.
5. Langsjoen P, Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994; 15(suppl):S265-S272.
6. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens 1999; 13:203-208.
7. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J 2001; 94:1112-1117.
8. De Pinieux G, Chariot P, Ammi-Saïd M, et al. Lipidlowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42:333-337.
9. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997; 18(suppl):S137-S144.
10. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33:226-229.
11. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q10 levels in humans. Proc Natl Acad Sci U S A 1990; 87:8931-8934.
12. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ. Plasma coenzyme Q10 (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993; 46:1055-1057.
13. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005; 62:1709-1712.
14. Päivä H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78:60-68.
15. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99:1409-1412.
16. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49:2231-2237.
17. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007; 100:1400-1403.
18. Berthold HK, Naini A, Di Mauro S, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf 2006; 29:703-712.
19. Groneberg DA, Kindermann B, Althammer M, et al. Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells. Int J Biochem Cell Biol 2005; 37:1208-1218.
20. Hadj A, Pepe S, Rosenfeldt F. The clinical application of metabolic therapy for cardiovascular disease. Heart Lung Circ 2007; 16(suppl 3):S56-S64.
21. Pepe S, Marasco SF, Haas SJ, Sheeran FL, Krum H, Rosenfeldt FL. Coenzyme Q10 in cardiovascular disease. Mitochondrion 2007; 7(suppl 1):S154-S167.
22. Lönnrot K, Pörsti I, Alho H, Wu X, Hervonen A, Tolvanen JP. Control of arterial tone after long-term coenzyme Q10 supplementation in senescent rats. Br J Pharmacol 1998; 124:1500-1506.
23. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007; 9:389-396.
24. Radcliffe KA, Campbell WW. Statin myopathy. Curr Neurol Neurosci Rep 2008; 8:66-72.
25. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106:1024-1028.
26. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77:851-854.
27. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008; 168:721-727.
28. Rosenfeldt FL, Haas SJ, Krum H, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 2007; 21:297-306.
29. Yamagami T, Shibata N, Folkers K. Bioenergetics in clinical medicine. Studies on coenzyme Q10 and essential hypertension. Res Commun Chem Pathol Pharmacol 1975; 11:273-288.
30. Yamagami T, Shibata N, Folkers K. Study of coenzyme Q10. In: Folkers K, Yamamura Y, editors. Biomedical and clinical aspects of coenzyme Q10: proceedings of the International Symposium on Coenzyme Q10, held at Lake Yamanaka, Japan, September 16/17, 1976, a Naito Foundation symposium. Amsterdam: Elsevier Scientific Publishing Company; 1977:231-242.
31. Digiesi V, Cantini F, Brodbeck B. Effect of coenzyme Q10 on essential arterial hypertension. Curr Ther Res; 1990; 47:841-845.
32. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2:483-491.
33. Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lova-statin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001; 19:81-83.
34. Hidaka T, Fujii K, Funahashi I, Fukutomi N, Hosoe K. Safety assessment of coenzyme Q10 (CoQ10). Biofactors 2008; 32:199-208.
35. US Food and Drug Administration. Consumer Information on Dietary Supplements. Overview of Dietary Supplements. http://www.fda.gov/Food/DietarySupplements/ConsumerInformation/. Accessed May 25, 2010.
36. US Pharmacopeia. The USP Dietary Supplement Verification Program. http://www.usp.org/USPVerified/dietary-Supplements/. Accessed May 25, 2010.
37. Serebruany VL, Ordonez JV, Herzog WR, et al. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharmacol 1997; 29:16-22.
38. A close look at coenzyme Q10 and policosanol. Do these supplements live up to their claims for improving heart health? Harv Heart Lett 2002; 13:6.
39. Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990; 30:596-608.
40. Singh U, Devaraj S, Jialal I. Coenzyme Q10 supplementation and heart failure. Nutr Rev 2007; 65:286-293.
41. Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Physician 2005; 72:1065-1070.
42. Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002; 56:1137-1142.
43. Pepping J. Coenzyme Q10. Am J Health Syst Pharm 1999; 56:519-521.
44. Tomono Y, Hasegawa J, Seki T, Motegi K, Morishita N. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int J Clin Pharmacol Ther Toxicol 1986; 24:536-541.
45. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res 1998; 68:109-113.
46. Liu ZX, Artmann C. Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system. Altern Ther Health Med 2009; 15:42-46.
47. Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 2007; 7(suppl 1):S78-S88.
48. The United States Pharmacopeia. Ubidecarenone Capsules Monograph. 32nd Revision. Baltimore: United Book Press, 2009:1080.